AstraZeneca Bets Big on AI Healthtech with INR 166 Cr Bengaluru Hub Expansion

The expanded facility will focus on advanced clinical research, AI-powered healthcare solutions, digital health technologies, and centralized data analytics to improve clinical trial outcomes.

Biopharma major AstraZeneca has announced a INR 166 Cr expansion of its global hub in Bengaluru, strengthening its AI-driven healthcare innovation and R&D operations in India.

The expanded facility will house around 1,300 employees and create 400 new jobs, focusing on advanced clinical research, AI-powered healthcare solutions, digital health technologies, and centralized data analytics to improve clinical trial outcomes.

"Our Global Hub in Bengaluru is a strategic investment that will play a vital role in advancing AstraZeneca's bold ambition to deliver 20 new medicines by 2030, by strengthening automated, scalable, data-driven, and patient-centric solutions. This step reflects our commitment to tapping into the world-class talent and ecosystem available in Karnataka to power the next generation of scientific innovation," said Jackie Crockford, Vice President, Global Business Services, AstraZeneca.

This marks AstraZeneca's second major India investment within a year, following its Global Innovation and Technology Centre (GITC) expansion in Chennai.

"This hub enhances our R&D capabilities by connecting us with India's exceptional scientific and technological expertise. The expansion will accelerate the development of innovative medicines and help us deliver across R&D, ultimately benefiting patients around the world," said Magnus Nord, Vice President, Global Patient Safety BioPharma, AstraZeneca.

The Bengaluru hub will play a key role in AI-enabled R&D, global business services, IT, and digital health operations. AstraZeneca's India workforce will now cross 4,000 employees.

Stay tuned for more such updates on Digital Health News